Global reach Amarin operates in over 90 markets worldwide with a mixed direct and syndicate distribution model, indicating opportunities to expand partnerships and licensing arrangements in regions where vascepa-like therapies are becoming more prevalent.

Cardiovascular focus Core emphasis on reducing cardiovascular disease burden and robust clinical evidence supports opportunities to upsell or co-market cardiovascular risk reduction therapies, diagnostics, and lifestyle management collaborations with payers and clinics.

Licensing growth Notable licensing and royalty revenue growth alongside stable U.S. Vascepa sales suggests potential to pursue additional co-development or royalty-backed deals with emerging cardiovascular assets or generic entrants in key markets.

IP litigation risk Ongoing patent litigation and high-stakes Hatch-Waxman considerations heighten the value of strategic alliances and out-licensing opportunities to accelerate safe market access and diversify legal risk across regions.

Financial and partnerships Moderate revenue scale with a global footprint and a sizeable funding base presents a ripe environment for strategic collaborations with CROs, biotech partners, and distributors to accelerate pipeline commercialization and geographic expansion.